The pharmacokinetics of rituximab following an intravitreal injection
Authors:
- Antonio J. Grillo-LopezAGAntonio J. Grillo-Lopez
- Michael R. RobinsonMRMichael R. Robinson
- 1 May 2006
- journal article
- Published by Elsevier in Experimental Eye Research
- Vol. 82 (5) , 760-766
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Concepts in radiotherapy and immunotherapy: Anti-CD20 mechanisms of action and targetsSeminars in Oncology, 2005
- Immunopathology of progressive subretinal fibrosis: A variant of sympathetic ophthalmiaAmerican Journal of Ophthalmology, 2004
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- Anti B cell therapy (rituximab) in the treatment of autoimmune diseasesCurrent Opinion in Pharmacology, 2004
- Ocular Pharmacokinetics of Fluocinolone Acetonide After Retisert™ Intravitreal Implantation in Rabbits Over a 1-Year PeriodJournal of Ocular Pharmacology and Therapeutics, 2004
- Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvementHistorical imageOphthalmology, 2002
- Primary intracerebral malignant lymphoma: report of 248 casesJournal of Neurosurgery, 2000
- Osmotic Blood-Brain Barrier Modification: Monoclonal Antibody, Albumin, and Methotrexate Delivery to Cerebrospinal Fluid and BrainNeurosurgery, 1985
- Physiology of the choroidal vascular bedInternational Ophthalmology, 1983
- The Albumin Exchange in the Rabbit EyeActa Physiologica Scandinavica, 1964